[A clinical trial of the effectiveness and tolerance of bepridil in unstable angina pectoris].
Bepridil, a new anti-anginal drug, was given in a daily dosage of 400 to 600 mg to twenty patients with unstable angina pectoris. The trial was designed to evaluate the effectiveness of bepridil in this indication and to determine the optimal dosage. A positive response evidenced by the arrest of progression towards infarction was recorded in 17 patients. Tolerance was satisfactory in 19 cases: in one diabetic patient under insulin symptoms of hypoglycemia resolved once insulin was discontinued. With the dosages used the effectiveness of bepridil in unstable angina pectoris is similar to that recorded in effort angina with 300 mg per day.
D000328:Adult; D000368:Aged; D000788:Angina Pectoris, Variant / Q000188:drug therapy*; D015764:Bepridil; D002986:Clinical Trials as Topic; D003329:Coronary Vasospasm / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines / Q000009:adverse effects / Q000627:therapeutic use*
D011759:Pyrrolidines; D015764:Bepridil
Etude clinique de l'efficacité et de la tolérance du bépridil dans l'angor instable.